{"id":8536,"date":"2024-03-24T12:43:24","date_gmt":"2024-03-24T12:43:24","guid":{"rendered":"https:\/\/news.talkwithrattan.com\/index.php\/2024\/03\/24\/bharat-biotech-begins-clinical-trials-of-tb-vaccine-on-adults-in-india-times-of-india\/"},"modified":"2024-03-24T12:43:24","modified_gmt":"2024-03-24T12:43:24","slug":"bharat-biotech-begins-clinical-trials-of-tb-vaccine-on-adults-in-india-times-of-india","status":"publish","type":"post","link":"https:\/\/news.talkwithrattan.com\/index.php\/2024\/03\/24\/bharat-biotech-begins-clinical-trials-of-tb-vaccine-on-adults-in-india-times-of-india\/","title":{"rendered":"Bharat Biotech begins clinical trials of TB vaccine on adults in India &#8211; Times of India"},"content":{"rendered":"<div style=\"text-align:center\"><img loading=\"lazy\" decoding=\"async\" width=\"1280\" height=\"720\" src=\"https:\/\/i0.wp.com\/static.toiimg.com\/photo\/msid-108750545,imgsize-269395.cms?resize=1280,720&amp;ssl=1\" class=\"attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"Bharat Biotech begins clinical trials of TB vaccine on adults in India &#8211; Times of India\" title=\"Bharat Biotech begins clinical trials of TB vaccine on adults in India &#8211; Times of India\" \/><\/div>\n<div>HYDERABAD: <!-- -->Bharat Biotech<!-- --> International Ltd on Sunday said it started <!-- -->clinical trials<!-- --> of the <!-- -->Tuberculosis<!-- --> vaccine <!-- -->Mtbvac<!-- --> on adults in India. <br \/>This is the first vaccine against Tuberculosis derived from a human source by the Spanish biopharmaceutical company, <!-- -->Biofabri<!-- -->, a press release from Bharat Biotech said. <br \/>The release said that Mtbvac is being developed for two purposes; firstly, as a more effective and potentially longer-lasting vaccine than BCG ( Bacillus Calmette Guerin) for newborns and secondly, for the prevention of TB in adults and adolescents, for whom there is currently no effective vaccine. <br \/>The trials are carried out by Bharat Biotech in close collaboration with Biofabri. Trials to evaluate the safety and immunogenicity of Mtbvac have started with a pivotal safety, immunogenicity and efficacy trial which has been planned to start in 2025, the release said. <br \/>It is a giant step to test in adults and adolescents in the country where 28 per cent of the world&#8217;s TB cases accumulate. <br \/>TB remains one of the world&#8217;s leading infectious causes of death, especially in India, Esteban Rodriguez, CEO of Biofabri said. Krishna Ella, Executive Chairman Bharat Biotech said &#8220;Our quest for a more effective vaccine against Tuberculosis received a big boost today, with clinical trials in India. Our goal to develop TB vaccines to prevent disease in adults and adolescents has taken a big step today.&#8221; <br \/>The Mtbvac vaccine has passed several milestones before entering clinical trials in India. After the recent completion of a Phase-2 dose finding trial, a double-blind controlled Phase-3 clinical trial in newborns has been started in 2023 to compare the vaccine with the current BCG vaccine. <br \/>As many as 7,000 newborns from South Africa, 60 from Madagascar and 60 from Senegal will be vaccinated. To date, more than 1,900 babies have been vaccinated, the release added.<\/div>\n<p><script>!(function(f, b, e, v, n, t, s) {\n    function loadFBEvents(isFBCampaignActive) {\n      if (!isFBCampaignActive) {\n        return;\n      }\n      (function(f, b, e, v, n, t, s) {\n        if (f.fbq) return;\n        n = f.fbq = function() {\n          n.callMethod ? n.callMethod(...arguments) : n.queue.push(arguments);\n        };\n        if (!f._fbq) f._fbq = n;\n        n.push = n;\n        n.loaded = !0;\n        n.version = '2.0';\n        n.queue = [];\n        t = b.createElement(e);\n        t.async = !0;\n        t.defer = !0;\n        t.src = v;\n        s = b.getElementsByTagName(e)[0];\n        s.parentNode.insertBefore(t, s);\n      })(f, b, e, 'https:\/\/connect.facebook.net\/en_US\/fbevents.js', n, t, s);\n      fbq('init', '593671331875494');\n      fbq('track', 'PageView');\n    };\n    function loadGtagEvents(isGoogleCampaignActive) {\n      if (!isGoogleCampaignActive) {\n        return;\n      }\n      var id = document.getElementById('toi-plus-google-campaign');\n      if (id) {\n        return;\n      }\n      (function(f, b, e, v, n, t, s) {\n        t = b.createElement(e);\n        t.async = !0;\n        t.defer = !0;\n        t.src = v;\n        t.id = 'toi-plus-google-campaign';\n        s = b.getElementsByTagName(e)[0];\n        s.parentNode.insertBefore(t, s);\n      })(f, b, e, 'https:\/\/www.googletagmanager.com\/gtag\/js?id=AW-877820074', n, t, s);\n    };\n    function loadSurvicateJs(allowedSurvicateSections = []){\n      const section =  window.location.pathname.split('\/')[1]\n      const isHomePageAllowed = window.location.pathname === '\/' && allowedSurvicateSections.includes('homepage')\n      if(allowedSurvicateSections.includes(section) || isHomePageAllowed){\n        (function(w) {\n          var s = document.createElement('script');\n          s.src=\"https:\/\/survey.survicate.com\/workspaces\/0be6ae9845d14a7c8ff08a7a00bd9b21\/web_surveys.js\";\n          s.async = true;\n          var e = document.getElementsByTagName('script')[0];\n          e.parentNode.insertBefore(s, e);\n        })(window);\n      }\n    }\n    window.TimesApps = window.TimesApps || {};\n    var TimesApps = window.TimesApps;\n    TimesApps.toiPlusEvents = function(config) {\n      var isConfigAvailable = \"toiplus_site_settings\" in f && \"isFBCampaignActive\" in f.toiplus_site_settings && \"isGoogleCampaignActive\" in f.toiplus_site_settings;\n      var isPrimeUser = window.isPrime;\n      if (isConfigAvailable && !isPrimeUser) {\n        loadGtagEvents(f.toiplus_site_settings.isGoogleCampaignActive);\n        loadFBEvents(f.toiplus_site_settings.isFBCampaignActive);\n        loadSurvicateJs(f.toiplus_site_settings.allowedSurvicateSections);\n      } else {\n        var JarvisUrl=\"https:\/\/vsp1jarvispvt.indiatimes.com\/v1\/feeds\/toi_plus\/site_settings\/643526e21443833f0c454615?db_env=published\";\n        window.getFromClient(JarvisUrl, function(config){\n          if (config) {\n            loadGtagEvents(config?.isGoogleCampaignActive);\n            loadFBEvents(config?.isFBCampaignActive);\n            loadSurvicateJs(config?.allowedSurvicateSections);\n          }\n        })\n      }\n    };\n  })(\n    window,\n    document,\n    'script',\n  );<\/script><br \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>HYDERABAD: Bharat Biotech International Ltd on Sunday said it started clinical trials of the Tuberculosis vaccine Mtbvac on adults in India. This is the first vaccine against Tuberculosis derived from a human source by the Spanish biopharmaceutical company, Biofabri, a press release from Bharat Biotech said. The release said that Mtbvac is being developed for [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":8537,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"tdm_status":"","tdm_grid_status":"","fifu_image_url":"https:\/\/static.toiimg.com\/photo\/msid-108750545,imgsize-269395.cms","fifu_image_alt":"","footnotes":""},"categories":[604],"tags":[6174,4509,6157,13154,13153,13155,289,13156,13152,273,13151,13150,272,4985,13149,13157],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/posts\/8536"}],"collection":[{"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/comments?post=8536"}],"version-history":[{"count":1,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/posts\/8536\/revisions"}],"predecessor-version":[{"id":8538,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/posts\/8536\/revisions\/8538"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/media\/8537"}],"wp:attachment":[{"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/media?parent=8536"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/categories?post=8536"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/tags?post=8536"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}